Australian bat lyssavirus: implications for public health
| Autor: | Jodie Powell, Penny Hutchinson, Bradley J McCall, Vikram L. Vaska, Jane E. Francis, Clare Nourse |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Australian bat lyssavirus
medicine.medical_specialty biology Transmission (medicine) business.industry Public health Australia General Medicine Disease Vectors biology.organism_classification Virology Rabies immunoglobulin Rabies vaccine Chiroptera Rhabdoviridae Infections medicine Animals Humans Infection control Lyssavirus Bites and Stings Public Health business medicine.drug |
| Zdroj: | Medical Journal of Australia. 201:647-649 |
| ISSN: | 1326-5377 0025-729X |
| DOI: | 10.5694/mja13.00261 |
| Popis: | Australian bat lyssavirus (ABLV) infection in humans is rare but fatal, with no proven effective therapy. ABLV infection can be prevented by administration of a post-exposure prophylaxis regimen of human rabies immunoglobulin and rabies vaccine. All Australian bats (flying foxes and microbats) should be considered to be carrying ABLV unless proven otherwise. Any bat-related injury (bite, scratch or mucosal exposure to bat saliva or neural tissue) should be notified immediately to the relevant public health unit - no matter how small the injury or how long ago it occurred. Human-to-human transmission of ABLV has not been reported but is theoretically possible. Standard infection control precautions should be employed when managing patients with suspected or confirmed ABLV infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text